Wednesday October 22, 8:32 am ET
Novel Insulin Formulation Provides for Glucose-regulated Insulin Delivery
BEVERLY, Mass. & NEW YORK--(BUSINESS WIRE)--SmartCells, Inc. and the Juvenile Diabetes Research Foundation (JDRF) today announced a partnership to advance SmartCells’ SmartInsulin™ for the treatment of type 1 diabetes. SmartInsulin will be a once-a-day, glucose-regulated subcutaneous insulin formulation for treating diabetes. SmartInsulin is injectable, like today’s currently available insulins, but designed to maintain continuous, tight control of blood glucose levels while reducing the risk of hypoglycemia – like the pancreas does automatically in the absence of diabetes. As part of the agreement, JDRF will provide $1 million in first-year funding to support preclinical safety and efficacy testing. The partnership is structured to support milestone-based funding through proof-of-concept human clinical trials.
October 22, 2008
From The News Wire: $1Million JDRF IDDP with SmartCells
SmartCells, Inc. and Juvenile Diabetes Research Foundation Announce Partnership and $1 Million Funding to Advance SmartInsulin(TM) for Type 1 Diabetes